Together, these data show that ADAM2 is a cancer-testis antigen expressed in a wide variety of tumor tissues, including a high proportion of human lung cancers, and profoundly affects the tumor immune microenvironment with implications for immune therapy. This evidence concerns the gene ADAM2 and lung carcinoma.